191 related articles for article (PubMed ID: 37875466)
1. Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.
Crispin-Ortuzar M; Woitek R; Reinius MAV; Moore E; Beer L; Bura V; Rundo L; McCague C; Ursprung S; Escudero Sanchez L; Martin-Gonzalez P; Mouliere F; Chandrananda D; Morris J; Goranova T; Piskorz AM; Singh N; Sahdev A; Pintican R; Zerunian M; Rosenfeld N; Addley H; Jimenez-Linan M; Markowetz F; Sala E; Brenton JD
Nat Commun; 2023 Oct; 14(1):6756. PubMed ID: 37875466
[TBL] [Abstract][Full Text] [Related]
2. Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study.
Yin R; Guo Y; Wang Y; Zhang Q; Dou Z; Wang Y; Qi L; Chen Y; Zhang C; Li H; Jian X; Ma W
Acad Radiol; 2023 Sep; 30 Suppl 2():S192-S201. PubMed ID: 37336707
[TBL] [Abstract][Full Text] [Related]
3. Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Rundo L; Beer L; Escudero Sanchez L; Crispin-Ortuzar M; Reinius M; McCague C; Sahin H; Bura V; Pintican R; Zerunian M; Ursprung S; Allajbeu I; Addley H; Martin-Gonzalez P; Buddenkotte T; Singh N; Sahdev A; Funingana IG; Jimenez-Linan M; Markowetz F; Brenton JD; Sala E; Woitek R
Front Oncol; 2022; 12():868265. PubMed ID: 35785153
[TBL] [Abstract][Full Text] [Related]
4. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
5. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Arend RC; Londoño AI; Montgomery AM; Smith HJ; Dobbin ZC; Katre AA; Martinez A; Yang ES; Alvarez RD; Huh WK; Bevis KS; Straughn JM; Estes JM; Novak L; Crossman DK; Cooper SJ; Landen CN; Leath CA
Mol Cancer Res; 2018 May; 16(5):813-824. PubMed ID: 29523763
[TBL] [Abstract][Full Text] [Related]
6. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
7. Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram.
Li H; Cai S; Deng L; Xiao Z; Guo Q; Qiang J; Gong J; Gu Y; Liu Z
Eur Radiol; 2023 Aug; 33(8):5298-5308. PubMed ID: 36995415
[TBL] [Abstract][Full Text] [Related]
8. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract][Full Text] [Related]
9. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
11. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an ultrasound‑based radiomics nomogram to predict lymph node status in patients with high-grade serous ovarian cancer: a retrospective analysis.
Qi Y; Liu J; Wang X; Zhang Y; Li Z; Qi X; Huang Y
J Ovarian Res; 2024 Feb; 17(1):48. PubMed ID: 38389075
[TBL] [Abstract][Full Text] [Related]
13. Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer.
Deen SS; Priest AN; McLean MA; Gill AB; Brodie C; Crawford R; Latimer J; Baldwin P; Earl HM; Parkinson C; Smith S; Hodgkin C; Patterson I; Addley H; Freeman S; Moyle P; Jimenez-Linan M; Graves MJ; Sala E; Brenton JD; Gallagher FA
Sci Rep; 2019 Jul; 9(1):10742. PubMed ID: 31341212
[TBL] [Abstract][Full Text] [Related]
14. The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
Rawert FL; Luengas-Würzinger V; Claßen-Gräfin von Spee S; Baransi S; Schuler E; Carrizo K; Dizdar A; Mallmann P; Lampe B
Arch Gynecol Obstet; 2022 Nov; 306(5):1665-1672. PubMed ID: 35357582
[TBL] [Abstract][Full Text] [Related]
15. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
16. Resistance prediction in high-grade serous ovarian carcinoma with neoadjuvant chemotherapy using data-independent acquisition proteomics and an ovary-specific spectral library.
Qian L; Zhu J; Xue Z; Gong T; Xiang N; Yue L; Cai X; Gong W; Wang J; Sun R; Jiang W; Ge W; Wang H; Zheng Z; Wu Q; Zhu Y; Guo T
Mol Oncol; 2023 Aug; 17(8):1567-1580. PubMed ID: 36855266
[TBL] [Abstract][Full Text] [Related]
17. Development of MRI-Based Radiomics Model to Predict the Risk of Recurrence in Patients With Advanced High-Grade Serous Ovarian Carcinoma.
Li HM; Gong J; Li RM; Xiao ZB; Qiang JW; Peng WJ; Gu YJ
AJR Am J Roentgenol; 2021 Sep; 217(3):664-675. PubMed ID: 34259544
[No Abstract] [Full Text] [Related]
18. Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment.
Yi X; Liu Y; Zhou B; Xiang W; Deng A; Fu Y; Zhao Y; Ouyang Q; Liu Y; Sun Z; Zhang K; Li X; Zeng F; Zhou H; Chen BT
Biomed Pharmacother; 2021 Jan; 133():111013. PubMed ID: 33227705
[TBL] [Abstract][Full Text] [Related]
19. Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
De Jong D; Otify M; Chen I; Jackson D; Jayasinghe K; Nugent D; Thangavelu A; Theophilou G; Laios A
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363568
[TBL] [Abstract][Full Text] [Related]
20. Pathological response of ovarian cancer to neoadjuvant chemotherapy.
Ivantsov AO
Chin Clin Oncol; 2018 Dec; 7(6):59. PubMed ID: 30509080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
